Lupin launches Merzee capsules in the United States
Drug Approval

Lupin launches Merzee capsules in the United States

Merzee is a generic equivalent of Taytulla of Allergan Pharmaceuticals International

  • By IPP Bureau | April 07, 2022

Lupin announced that it has launched Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg, in the US market, under exclusive license, marketing and distribution agreement with Slayback Pharma. Slayback had earlier launched this product in the US in February 2021.

 Merzee  (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg is a generic equivalent of Taytulla (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg of Allergan Pharmaceuticals International.

Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1 mg/20 mcg (RLD: Taytulla) had estimated annual sales of US $ 90 million in the U.S. (IQVIA MAT February 2022).

Upcoming E-conference

Other Related stories

Startup

Digitization